Le Lézard
Classified in: Health, Business
Subject: VEN

Patientco Primed to Help More Health Systems Rethink Patient Payments with Strategic Growth Investment Led by Accel-KKR


ATLANTA and MENLO PARK, Calif., July 25, 2018 /PRNewswire/ -- Patientco, a next-generation patient billing and payments technology company, announced today it has raised $28 million in Series B growth capital.  This investment was led by Accel-KKR with participation from existing investor BlueCross BlueShield Venture Partners / Sandbox Advantage Fund. The capital will be used to accelerate Patientco's growth in the $5B+ patient payments market, expand sales and marketing throughout the U.S., and fuel continued product innovation within the company's industry-leading patient billing and payments platform.

"We are solving for an unprecedented affordability crisis in healthcare," said Bird Blitch, co-founder and CEO of Patientco. "Health Systems have an opportunity to create a superior patient financial experience by leveraging smarter technology which turns patient payments into an economic growth engine. We are excited to partner with Accel-KKR to continue our growth and help more health systems solve this complex challenge."

Accel-KKR's investment comes on the heels of a string of successful milestones for Patientco including: reaching 10 million unique patient users, crossing $1B in payments processed, and serving more than 2,000 healthcare locations across the U.S. with its patient billing and payments technology. Patientco continues to bring together the best in FinTech and Payments technology to create a superior patient financial experience and deliver significant financial outcomes for its Health System clients.

"Patientco has a differentiated approach to the patient payments problem in healthcare, leveraging its end-to-end platform to make every patient financial engagement better than the last. We believe Patientco will make a lasting positive impact on healthcare, both for patients and health systems on the Patientco platform," remarked David Cusimano, Principal at Accel-KKR. "No other payments company in the market offers a seamless patient experience while being able to handle the volume that comes from large health systems. We are very excited to be a part of this next stage of Patientco's success," added Greg Williams, Managing Director at Accel-KKR.

"Patientco has been a tremendous growth story," said Tom Hawes, M.D. Managing Director at Sandbox Industries, on behalf of BlueCross BlueShield Venture Partners.  "The management team continues to execute on a compelling strategy which creates differentiated outcomes for Health Systems alongside 95% positive patient feedback on their payment experience. We are pleased to have Accel-KKR join the Patientco family."

About Accel-KKR
Accel-KKR is a technology-focused investment firm with $4.3 billion in capital commitments. The firm focuses on software and IT-enabled businesses well-positioned for topline and bottom-line growth. At the core of Accel-KKR's investment strategy is a commitment to developing strong partnerships with the management teams of its portfolio companies and a focus on building value through significant resources available through the Accel-KKR network. Accel-KKR focuses on middle-market companies and provides a broad range of capital solutions including buyout capital, minority-growth investments, and credit alternatives. Accel-KKR also invests across a wide range of transaction types including private company recapitalizations, divisional carve-outs and going-private transactions. Accel-KKR is headquartered in Menlo Park with additional offices in Atlanta and London.

About BlueCross BlueShield Venture Partners
BlueCross BlueShield Venture Partners, L.P. is a corporate venture fund licensed by the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield companies. The fund invests in promising emerging companies of strategic relevance to Blue Cross and Blue Shield companies. Sandbox Industries is the exclusive provider of investment management services to BlueCross BlueShield Venture Partners. For more information, visit www.bcbsvp.com.

About Patientco
Patientco is a payment technology company founded specifically to re-think the patient payment experience in healthcare by bringing together intuitive consumer payment tools and world-class payment infrastructure backed by data-led design to create a superior patient billing experience and deliver more payments to Health Systems. Patientco is a proud cohort of the Backed By ATL initiative from the Metro Atlanta Chamber and alumni of Georgia Tech's Advanced Technology Development Center (ATDC) incubator program. Patientco is making healthcare better one payment at a time. Visit Patientco online at Patientco.com.

Media Contact:

Todd Fogarty
Kekst
212-521-4854
[email protected]

SOURCE Accel-KKR


These press releases may also interest you

at 07:45
Sensi.AI, a leader in AI-native, data, and analytics in senior care, today announced the appointment of in-home care leader Bob Roth to its Advisory Board. This partnership is an exciting validation of Sensi.AI's promise to enhance proactive,...

at 07:05
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...



News published on and distributed by: